Novartis Ag

Frank Stephan Kalthoff

Pascal Furet

Robin Alec Fairhurst

Robert Mah

Heinrich Rueeger

Frédéric Stauffer

Andreas Lerchner

Christian Ragot

The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.

Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases

The invention relates to the use of 1H-imidazo[4,5-]quinolinone derivatives and salts thereof in the treatment of protein and/or lipid kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases; 1H-imidazo[4,5-]quinolinone derivatives for use in the treatment of protein and/or lipid kinase dependent diseases; a method of treatment against said diseases, comprising administering the 1H-imidazo[4,5-]quinolinone derivatives to a warm-blooded animal, especially a human; pharmaceutical preparations comprising an 1H-imidazo[4,5-]quinolinone derivative, especially for the treatment of a protein and/or lipid kinase dependent disease; novel 1H-imidazo[4,5-]quinolinone derivatives; and a process for the preparation of the novel 1H-imidazo[4,5-]quinolinone derivatives.

[object Object]

Growing community of inventors

Vienna, Austria

Frank Stephan Kalthoff